Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 9/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 3/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5986044 | 0.90 | BDKRB1 (0.51) | BDKRB1ALDH1A1POLBMAPTMMP2 | |
| SCHEMBL5986046 | 0.90 | BDKRB1 (0.51) | BDKRB1ALDH1A1POLBMAPTMMP2 | |
| SCHEMBL4519076 | 0.87 | ALDH1A1 (0.67) | BDKRB1ALDH1A1POLBMAPTMMP2 | |
| SCHEMBL4523939 | 0.87 | ALDH1A1 (0.67) | BDKRB1ALDH1A1POLBMAPTMMP2 | |
| SCHEMBL4524747 | 0.83 | BDKRB1 (0.40) | BDKRB1ALDH1A1MAPT | |
| SCHEMBL4524472 | 0.83 | BDKRB1 (0.40) | BDKRB1ALDH1A1MAPT | |
| SCHEMBL3534971 | 0.79 | ALDH1A1 (0.76) | BDKRB1ALDH1A1POLBMAPT | |
| SCHEMBL3534966 | 0.79 | ALDH1A1 (0.76) | BDKRB1ALDH1A1POLBMAPT | |
| SCHEMBL14307677 | 0.73 | BDKRB1 (0.40) | BDKRB1ALDH1A1MAPT | |
| SCHEMBL4177150 | 0.72 | BDKRB1 (0.46) | BDKRB1ALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054460-A1 | Piperazine derivatives and methods of use | CHEN JIAN J | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054460-A1 | Piperazine derivatives and methods of use | PTGES, PTGES2, PTGIS | BDKRB1 259/4885ALDH1A1 184/4885POLB 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.